A multicenter study evaluating the sensitization potential of enamel matrix derivative after treatment of two infrabony defects

Journal of Periodontology

Volumn 75, Issue 7, 2004, Pages 1001-1008

  Froum, Stuart ^a,f   Weinberg, Mea ^a   Novak, John ^b   Mailhot, Jason ^c   Mellonig, James ^d   Van Dyke, Thomas ^e   McClain, Pamela ^f   Papapanou, Panos N ^g   Childers, Gail ^f   Ciancio, Sebastian ^h   Blieden, Tim ⁱ   Polson, Alan ^j   Greenstein, Gary ^f   Yukna, Raymond ^k   Lynn Wallace, Marshall ^f   Patters, Mark ^l   Wagener, Charles ^f  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e BOSTON UNIVERSITY   (United States)

^f Columbia University ^*  (United States)

^g University at Buffalo ^*  (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k LOUISIANA STATE UNIVERSITY   (United States)

^l UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

Enamel matrix derivative adverse effects; Multicenter studies; Periodontal diseases theraphy; Risk factor; Wound healing

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; CITRIC ACID; CODEINE; CORTICOSTEROID DERIVATIVE; DOXYCYCLINE; EDETIC ACID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PENICILLIN V; PREDNISONE; SILDENAFIL; SULFANILAMIDE DERIVATIVE; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY REACTION; ARTICLE; BONE DEFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DENTAL SURGERY; DRUG HYPERSENSITIVITY; ENAMEL; ERYTHEMA; FEMALE; GINGIVITIS; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MOUTH ABSCESS; MOUTH LESION; MOUTH ULCER; MULTICENTER STUDY; PATIENT REFERRAL; PATIENT SELECTION; PENICILLIN ALLERGY; PERIODONTAL DISEASE; PERIOSTEUM GRAFT; PH; POSTOPERATIVE EDEMA; POSTOPERATIVE INFECTION; POSTOPERATIVE PAIN; PRESSURE; PRIVATE PRACTICE; PRURITUS; SENSITIZATION; SURGICAL TECHNIQUE; SUTURING METHOD; TINEA CRURIS; TOOTH ROOT;

EID: 4444296589     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2004.75.7.1001     Document Type: Article

References (26)

1. Hammarström L. Enamel matrix, cementum development and regeneration. J Clin Periodontol 1997;24: 658-668.
2. Heijl L. Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report. J Clin Periodontol 1997;24:693-696.
3. Mellonig JT. Enamel matrix derivative for periodontal reconstructive surgery: Technique and clinical and histologic case report. Int J Periodontics Restorative Dent 1999;19:9-19.
4. Yukna RA, Mellonig J. Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10-case series. J Periodontol 2000;71:752-759.
5. Sculean A, Chiantella GC, Windisch P, Donos N. Clinical and histological evaluation of human intrabony defects treated with an enamel matrix protein derivative (Emdogain). Int J Periodontics Restorative Dent 2000;20:374-381.
6. Windisch P, Sculean A, Klein F, et al. Comparison of clinical, radiographic and histometric measurements following treatment with guided tissue regeneration or enamel matrix proteins in human periodontal defects. J Periodontol 2002;73:409-417.
7. Heijl L, Heden G, Svärdström G, Östgren A. Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects. J Clin Periodontol 1997;24:705-714.
8. Sculean A, Reich E, Chiantella G, Brecx M. Treatment of intrabony periodontal defects with an enamel matrix protein derivative (Emdogain). A report of 32 cases. Int J Periodontics Restorative Dent 1999;19:157-163.
9. Heden G, Wennström J, Lindhe J. Periodontal tissue alterations following enamel matrix derivative treatment of periodontal sites with angular bone defects. A series of case reports. J Clin Periodontol 1999;26:855-860.
10. Okuda K, Momose M, Miyazaki A, et al. Enamel matrix derivative in the treatment of human intrabony osseous defects. J Periodontol 2000;71:1821-1828.
11. Froum SJ, Weinberg MA, Rosenberg E, Tarnow D. A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: A 12-month re-entry study. J Periodontol 2001;72:25-34.
12. Sculean A, Donos N, Windisch P, et al. Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. J Periodontal Res 1999;34:310-322.
13. Sculean A, Donos N, Blaes A, et al. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split mouth study. J Periodontol 1999;70:255-262.
14. Pontoriero R, Wennström J, Lindhe J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study. J Clin Periodontol 1999;26:833-840.
15. Silvestri M, Ricci G, Rasperini G, Sartors S, Cattaneo V. Comparison of treatments of intrabony defects with enamel matrix derivative, guided tissue regeneration with a non-resorbable membrane and Widman modified flap. A pilot study. J Clin Periodontol 2000;27:603-610.
16. Sculean A, Windisch P, Chiantella GC, Donos N, Brecx M, Reich E. Treatment of intrabony defects with enamel matrix proteins and GTR. A prospective controlled clinical study. J Clin Periodontol 2001;28:397-403.
17. Froum S, Lemler J, Horowitz T, Davidson B. The use of enamel matrix derivative in the treatment of periodontal osseous defects: A clinical decision tree based on biologic principles of regeneration. Int J Periodontics Restorative Dent 2001;24:437-449.
18. Boyan BD, Weesner TC, Lohmann CH, et al. Porcine fetal enamel matrix derivative enhances bone formation induced by demineralized freeze-dried bone allograft in vivo. J Periodontol 2000;71:1278-1286.
19. Lekovic V, Camargo PM, Weinlaender M, Nedic M, Aleksic Z, Kenney EB. A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. J Periodontol 2000;71:1110-1116.
20. Scheyer ET, Velasquez-Plata D, Brunsvold MA, Lasho DJ, Mellonig J. A clinical comparison of a bovine-derived xenograft used alone and in combination with enamel matrix derivative for the treatment of periodontal osseous defects. J Periodontol 2002;73:423-432.
21. Sculean A, Barbé G, Chiantella GC, Arweiler NB, Berakdar M, Brecx M. Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. J Periodontol 2002;73:401-408.
22. Zetterström O, Andersson C, Eriksson L, et al. Clinical safety of enamel matrix derivative (Emdogain) in the treatment of periodontal defects. J Clin Periodontol 1997; 24;697-704.
23. Heard RH, Mellonig JT, Brunsvold MA, Lasho DJ, Meffert RM, Cochran DL. Clinical evaluation of wound healing following multiple exposures to enamel matrix protein derivative in the treatment of intrabony periodontal defects. J Periodontol 2000;71:1715-1721.
24. Curtis JW, McLain JB, Hutchinson RA. The incidence and severity of complication and pain following periodontal surgery. J Periodontol 1985;56:597-601.
25. Chabanski MB, Gillam DG, Bulman JS, Newman HN. Prevalence of cervical dentine sensitivity in a population of patients referred to a specialist periodontology department. J Clin Periodontol 1996;23:989-992.
26. Croog SH, Baume RM, Nalbandian J. Pain response after psychological preparation for repeated periodontal surgery. J Am Dent Assoc 1994;125:1353-1360.